Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2026-01-30 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2026-01-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a formal letter from Glenmark Pharmaceuticals Limited addressed to stock exchanges, informing them about the scheduled earnings call for Q3 FY 2026 results. It includes details such as date, time, dial-in numbers, and contact information for clarifications. The document does not contain any financial data or results itself but serves as an announcement of the upcoming earnings call event. The length is short (1970 characters), and the content is clearly an invitation/notification rather than the transcript or report of the earnings call. Therefore, this document fits the category of a Call Transcript announcement or invitation, but since it is not the transcript itself, it is best classified as a Call Transcript (CT) type document, as it relates directly to the earnings call event. Given the nature of the document as an invitation to the earnings call, the classification is CT with high confidence.
2026-01-22 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-19 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for January 30, 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2025. It also mentions the closure of the trading window for insiders as per regulatory requirements. The document does not contain any financial data or results itself, nor does it include detailed financial analysis or reports. It is an announcement of a board meeting and related compliance information, not the financial report or results. The document length is short (1982 characters), and it serves as a notification rather than a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-19 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for January 30, 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2025. It also mentions the closure of the trading window for insiders as per regulatory requirements. The document does not contain any financial data or results itself, nor does it include detailed financial statements or analysis. It is an announcement of a board meeting and related compliance information, not the financial report or results. The document length is short (1982 characters), and it serves as a notification rather than a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-19 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding an ESG rating assigned by an external agency for the fiscal year 2025. It references SEBI Listing Regulations and clarifies that the rating was assigned independently without company engagement. The document is brief (2128 characters) and serves as a regulatory announcement rather than a detailed ESG report or annual report. It does not contain financial statements or detailed analysis, nor is it a certification or voting result. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to ESG rating disclosure.
2026-01-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.